Abeona Gene Therapy for Epidermolysis Bullosa Continues to Impress the FDA – Rare Disease Report
Rare Disease Report |
Abeona Gene Therapy for Epidermolysis Bullosa Continues to Impress the FDA
Rare Disease Report “EB-101 is an autologous gene-corrected cell therapeutic approach that utilizes a patient's own cells and genetically engineering them to produce the correct version of collagen, which helps hold skin on to the body, thereby reducing the number of … Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in … |
